Search

Your search keyword '"Paillot, B"' showing total 7 results
Start Over Author "Paillot, B" Database OpenAIRE
7 results on '"Paillot, B"'

1. A Novel 8-Predictors Signature to Predict Complicated Disease Course in Pediatric-onset Crohn’s Disease: A Population-based Study

Author

Sarter, Hélène, Savoye, Guillaume, Marot, Guillemette, Ley, Delphine, Turck, Dominique, Hugot, Jean-Pierre, Vasseur, Francis, Duhamel, Alain, Wils, Pauline, Princen, Fred, Colombel, Jean-Frédéric, Gower-Rousseau, Corinne, Fumery, Mathurin, Al Hameedi, R, Al Khatib, M, Al Turk, S, Agoute, E, Andre, J, Antonietti, M, Aouakli, A, Armand, A, Armengol-Debeir, L, Aroichane, I, Assi, F, Aubet, J, Auxenfants, E, Avram, A, Ayafi-Ramelot, F, Azzouzi, K, Bankovski, D, Barbry, B, Bardoux, N, Baron, P, Baudet, A, Bayart, P, Bazin, B, Bebahani, A, Becqwort, J, Bellati, S, Benet, V, Benali, H, Benard, C, Benguigui, C, Ben Soussan, E, Bental, A, Berkelmans, I, Bernet, J, Bernou, K, Bernou-Dron, C, Bertot, P, Bertiaux-Vandaële, N, Bertrand, V, Billoud, E, Biron, N, Bismuth, B, Bleuet, M, Blondel, F, Blondin, V, Bobula, M, Bohon, P, Bondjemah, V, Boniface, E, Bonkovski, D, Bonnière, P, Bonvarlet, E, Bonvarlet, P, Boruchowicz, A, Bostvironnois, R, Boualit, M, Bouazza, A, Bouche, B, Boudaillez, C, Bourgeaux, C, Bourgeois, M, Bourguet, A, Bourienne, A, Boutaleb, H, Bouthors, A, Branche, J, Bray, G, Brazier, F, Breban, P, Bridenne, M, Brihier, H, Bril, L, Brung-Lefebvre, V, Bulois, P, Burgiere, P, Butel, J, Canva, J, Canva-Delcambre, V, Capron, J, Cardot, F, Carette, S, Carpentier, P, Cartier, E, Cassar, J, Cassagnou, M, Castex, J, Catala, P, Cattan, S, Catteau, S, Caujolle, B, Cayron, G, Chandelier, C, Chantre, M, Charles, J, Charneau, T, Chavance-Thelu, M, Cheny, A, Chirita, D, Choteau, A, Claerbout, J, Clergue, P, Coevoet, H, Cohen, G, Collet, R, Colin, M, Colombel, J, Coopman, S, Cordiez, L, Corvisart, J, Cortot, A, Couttenier, F, Crinquette, J, Crombe, V, Dadamessi, I, Daoudi, H, Dapvril, V, Davion, T, Dautreme, S, Debas, J, Decoster, S, Degrave, N, Dehont, F, Delatre, C, Delcenserie, R, Delesalle, D, Delette, O, Delgrange, T, Delhoustal, L, Delmotte, J, Demmane, S, Deregnaucourt, G, Descombes, P, Desechalliers, J, Desmet, P, Desreumaux, P, Desseaux, G, Desurmont, P, Devienne, A, Devouge, E, Devred, M, Devroux, A, Dewailly, A, Dharancy, S, Di Fiore, A, Djedir, D, Djedir, R, Doleh, W, Dreher-Duwat, M, Dubois, R, Duburque, C, Ducatillon, P, Duclay, J, Ducrocq, B, Ducrot, F, Ducrotte, P, Dufilho, A, Duhamel, C, Dujardin, D, Dumant-Forest, C, Dupas, J, Dupont, F, Duranton, Y, Duriez, A, Duveau, N, El Achkar, K, El Farisi, M, Elie, C, Elie-Legrand, M, Elkhaki, A, Eoche, M, Essmaeel, E, Evrard, D, Evrard, J, Fatome, A, Filoche, B, Finet, L, Flahaut, M, Flamme, C, Foissey, D, Fournier, P, Foutrein-Comes, M, Foutrein, P, Fremond, D, Frere, T, Gallais, P, Gamblin, C, Ganga, S, Gerard, R, Geslin, G, Gheyssens, Y, Ghossini, N, Ghrib, S, Gilbert, T, Gillet, B, Godart, D, Godard, P, Godchaux, J, Godchaux, R, Goegebeur, G, Goria, O, Gottrand, F, Gower, P, Grandmaison, B, Groux, M, Guedon, C, Guerbeau, L, Gueroult-Dero, M, Guillard, J, Guillem, L, Guillemot, F, Guimberd, D, Haddouche, B, Hakim, S, Hanon, D, Hautefeuille, V, Heckestweiller, P, Hecquet, G, Hedde, J, Hellal, H, Henneresse, P, Heyman, B, Heraud, M, Herve, S, Hochain, P, Houssin-Bailly, L, Houcke, P, Huguenin, B, Iobagiu, S, Istanboli, S, Ivanovic, A, Iwanicki-Caron, I, Janicki, E, Jarry, M, Jeu, J, Joly, J, Jonas, C, Jouvenet, A, Katherin, F, Kerleveo, A, Khachfe, A, Kiriakos, A, Kiriakos, J, Klein, O, Kohut, M, Kornhauser, R, Koutsomanis, D, Laberenne, J, Lacotte, E, Laffineur, G, Lagarde, M, Lalanne, A, Lalieu, A, Lannoy, P, Lapchin, J, Laprand, M, Laude, D, Leblanc, R, Lecieux, P, Lecleire, S, Leclerc, N, Le Couteulx, C, Ledent, J, Lefebvre, J, Lefiliatre, P, Le Goffic, C, Legrand, C, Le Grix, A, Lelong, P, Leluyer, B, Lemaitre, C, Lenaerts, C, Lepeut, G, Lepileur, L, Leplat, A, Lepoutre-Dujardin, E, Leroi, H, Leroy, M, Le Roy, P, Lesage, B, Lesage, J, Lesage, X, Lescanne-Darchis, I, Lescut, J, Lescut, D, Leurent, B, Levy, P, Lhermie, M, Libier, L, Lion, A, Lisambert, B, Loge, I, Loire, F, Loreau, J, Louf, S, Louvet, A, Lubret, L, Luciani, M, Lucidarme, D, Lugand, J, Macaigne, O, Maetz, D, Maillard, D, Mancheron, H, Manolache, O, Marks-Brunel, A, Marre, C, Marti, R, Martin, F, Martin, G, Marzloff, E, Mathurin, P, Mauillon, J, Maunoury, V, Maupas, J, Medam Djomo, M, Mechior, C, Melki, Z, Mesnard, B, Metayer, P, Methari, L, Meurisse, B, Meurisse, F, Michaud, L, Mirmaran, X, Modaine, P, Monthe, A, Morel, L, Mortier, P, Moulin, E, Mouterde, O, Mozziconaci, N, Mudry, J, Nachury, M, Ngo, M, N’guyen Khac, Eric, Notteghem, B, Ollevier, V, Ostyn, A, Ouraghi, A, Oussadou, B, Ouvry, D, Paillot, B, Painchart, C, Panien-Claudot, N, Paoletti, C, Papazian, A, Parent, B, Pariente, B, Paris, J, Patrier, P, Paupard, T, Pauwels, B, Pauwels, M, Penninck, E, Petit, R, Piat, M, Piotte, S, Plane, C, Plouvier, B, Pollet, E, Pommelet, P, Pop, D, Pordes, C, Pouchain, G, Prades, P, Prevost, A, Prevost, J, Quartier, G, Quesnel, B, Queuniet, A, Quinton, J, Rabache, A, Rabelle, P, Raclot, G, Ratajczyk, S, Rault, D, Razemon, V, Reix, N, Renaut-Vantroys, T, Revillion, M, Riachi, G, Richez, C, Robinson, P, Rodriguez, J, Roger, J, Roux, J, Rudelli, A, Saber, A, Savoye, G, Schlossberg, P, Sefrioui, D, Segrestin, M, Seguy, D, Seminur, C, Serin, M, Seryer, A, Sevenet, F, Shekh, N, Silvie, J, Simon, V, Spyckerelle, C, Talbodec, N, Tavernier, N, Tchandeu, H, Techy, A, Thelu, J, Thevenin, A, Thiebault, H, Thomas, J, Thorel, J, Thuillier, C, Tielman, G, Tode, M, Toisin, J, Tonnel, J, Touchais, J, Toumelin, P, Touze, Y, Tranvouez, J, Triplet, C, Triki, N, Turck, D, Uhlen, S, Vaillant, E, Valmage, C, Vanco, D, Vandaele-Bertiaux, N, Vandamme, H, Vanderbecq, E, Vander Eecken, E, Vandermolen, P, Vandevenne, P, Vandeville, L, Vandewalle, A, Vandewalle, C, Vaneslander, P, Vanhoove, J, Vanrenterghem, A, Vanveuren, C, Varlet, P, Vasies, I, Verbiese, G, Verlynde, J, Vernier-Massouille, G, Vermelle, P, Verne, C, Vezilier-Cocq, P, Vigneron, B, Vincendet, M, Viot, J, Voiment, Y, Wacrenier, A, Waeghemaecker, L, Wallez, J, Wantiez, M, Wartel, F, Weber, J, Willocquet, J, Wizla, N, Wolschies, E, Zaharia, O, Zaoui, S, Zalar, A, Zaouri, B, Zellweger, A, Ziade, C, Beaugerie, L, Allez, M, Ruemmele, F, Lamer, A, Roy, M, CHU Lille, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Normandie Université (NU), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire de Reims (CHU Reims), Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Amiens-Picardie, Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Colloid Chemistry [Potsdam], Max Planck Institute of Colloids and Interfaces, Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), and Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Crohn’s disease, inflammatory bowel disease, complication, genetics, prediction, prognosis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background The identification of patients at high risk of a disabling disease course would be invaluable in guiding initial therapy in Crohn’s disease (CD). Our objective was to evaluate a combination of clinical, serological, and genetic factors to predict complicated disease course in pediatric-onset CD. Methods Data for pediatric-onset CD patients, diagnosed before 17 years of age between 1988 and 2004 and followed more than 5 years, were extracted from the population-based EPIMAD registry. The main outcome was defined by the occurrence of complicated behavior (stricturing or penetrating) and/or intestinal resection within the 5 years following diagnosis. Lasso logistic regression models were used to build a predictive model based on clinical data at diagnosis, serological data (ASCA, pANCA, anti-OmpC, anti-Cbir1, anti-Fla2, anti-Flax), and 369 candidate single nucleotide polymorphisms. Results In total, 156 children with an inflammatory (B1) disease at diagnosis were included. Among them, 35% (n = 54) progressed to a complicated behavior or an intestinal resection within the 5 years following diagnosis. The best predictive model (PREDICT-EPIMAD) included the location at diagnosis, pANCA, and 6 single nucleotide polymorphisms. This model showed good discrimination and good calibration, with an area under the curve of 0.80 after correction for optimism bias (sensitivity, 79%, specificity, 74%, positive predictive value, 61%, negative predictive value, 87%). Decision curve analysis confirmed the clinical utility of the model. Conclusions A combination of clinical, serotypic, and genotypic variables can predict disease progression in this population-based pediatric-onset CD cohort. Independent validation is needed before it can be used in clinical practice.

Published
2023
Full Text
View/download PDF

2. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Author

Nordlinger, B, Sorbye, H, Glimelius, B, Poston, Gj, Schlag, Pm, Rougier, P, Bechstein, Wo, Primrose, Jn, Walpole, Et, FINCH JONES, M, Jaeck, D, Mirza, D, Parks, Rw, Collette, L, Praet, M, Bethe, U, VAN CUTSEM, E, Scheithauer, W, Gruenberger, T, Hohenberger, W, Iveson, T, Karner, J, Levi, J, Hugh, T, DE GREVE, J, Chan, A, Davidson, B, Lindner, P, Peeters, M, Stein, B, Diamond, T, Ducreux, M, Lasser, P, Graeven, U, Paillot, B, Doran, J, Gouillat, C, Iesalnieks, I, Jauch, Kw, JAGOT LACOUSSIERE, P, Jansen, Rl, Koehne, H, Konopke, R, Otto, F, Sherlock, D, VAN HAZEL, G, Ackland, S, Bedenne, L, Bories, E, CLAVERO FABRI MC, Conroy, T, KAMINSKY FORRETT MC, Husseini, F, Karapetis, C, Mãœller, L, Price, T, Rosenberg, R, Schott, J, Tschmelitsch, J, VAN LAETHEM JL, Wals, J, Weimann, A, Arnaud, Jp, Arsene, D, Auby, D, Bhattacharya, S, Cebon, E, Cherqui, D, Confente, C, Dousset, B, Frickhofen, N, Frilling, A, Evan, P, Ganju, V, Hã–ffken, K, Lazorthes, F, Letoublon, C, Madroszyk, A, Nitti, Donato, Orr, B, Pariente, Ea, Pector, Jc, Raoul, Jl, Rees, M, Ridwelski, K, Rouanet, P, Toogood, Gj, Vergauwe, P, Wilke, Hj, Kaplan, R, Horiot, Jc, Littbrand, B, Awada, A, Stenning, S, Lejeune, F., Haukeland University Hospital, University of Bergen (UiB), Uppsala Universitet [Uppsala], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Chirurgie Viscérale, Hépatique et de Transplantation Multiorganes, Université Louis Pasteur - Strasbourg I, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), University Hospitals Leuven [Leuven], Centre Énergétique et Procédés (CEP), MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), and Université d'Angers (UA)

Subjects
Adult, Male, medicine.medical_specialty, Organoplatinum Compounds, Colorectal cancer, [SDV]Life Sciences [q-bio], 030230 surgery, Perioperative Care, 03 medical and health sciences, 0302 clinical medicine, Hepatic arterial infusion, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, business.industry, Liver Neoplasms, Hazard ratio, Cancer, General Medicine, Perioperative, Middle Aged, medicine.disease, Combined Modality Therapy, 3. Good health, Surgery, Oxaliplatin, Clinical trial, 030220 oncology & carcinogenesis, Female, Fluorouracil, Colorectal Neoplasms, Liver cancer, business, medicine.drug
Abstract

Summary Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Methods This parallel-group study reports the trial's final data for progression-free survival for a protocol unspecified interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were centrally randomised by minimisation, adjusting for centre and risk score. The primary objective was to detect a hazard ratio (HR) of 0·71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, number NCT00006479. Findings In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1–6) preoperative cycles and 115 (63%) patients received a median six (1–8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7·3% (from 28·1% [95·66% CI 21·3–35·5] to 35·4% [28·1–42·7]; HR 0·79 [0·62–1·02]; p=0·058) in randomised patients; 8·1% (from 28·1% [21·2–36·6] to 36·2% [28·7–43·8]; HR 0·77 [0·60–1·00]; p=0·041) in eligible patients; and 9·2% (from 33·2% [25·3–41·2] to 42·4% [34·0–50·5]; HR 0·73 [0·55–0·97]; p=0·025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0·04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group. Interpretation Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected patients. Funding Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer Institute, Sanofi-Aventis.

Published
2008
Full Text
View/download PDF

3. Raltitrexed versus standard leucovorin-modulated 5Fluorouracil: results form the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)

Author

Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Bianco AR, El Serafi M, Bedenne L, Paillot B, Mini E, Sanches E, Welch J, Colette L, Praet M, Wils J, CARLOMAGNO, Chiara, Popov, I, Carrato, A, Sobrero, A, Vincent, M, Kerr, D, Labianca, R, Bianco, Ar, El Serafi, M, Bedenne, L, Paillot, B, Mini, E, Sanches, E, Welch, J, Colette, L, Praet, M, Wils, J, and Carlomagno, Chiara

Subjects
adjuvant chemotherapy, colon
Abstract

the aim of the study was the non-inferiority of raltitrexed as compared with standard 5fluorouracil-folinic acid as adjuvant chemotherapy for radically resected colon cancer patients. 993 patinets have been randomized; the enrollement was prematurely closed when 17 raltitrexed-related deaths were recorded. The toxicity was higher in patinets treated with raltitrexed. RSF and OAS were slight inferion in patinets treated with raltitrexed. In conclusion, the study failed to demonstrate the non-inferiority of raltitrexed.

Published
2008

4. Concurrent concentrated chemoradiation therapy in squamous cell carcinoma of the esophagus: long term results of a national multicenter phase II study in 122 inoperable patients (FFCD 8803)

Author

Seitz, JF, Milan, C, Giovannini, M, Dumas, F, Cauvin, JM, Conroy, T, Francois, E, Renard, P, Votte-Lambert, A, Paillot, B, Bedenne, L, Canc, Federation Natl Ctr Lutte, Laboratoire de psychologie cognitive (LPC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), and Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)

Subjects
[SCCO.PSYC]Cognitive science/Psychology
Abstract

International audience; Objectives-Concomitant radiochemotherapy improves survival from inoperable esophageal cancer compared to radiotherapy alone. Several regimens of radiotherapy (standard or concentrated split course radiotherapy) are used, however the optimum protocol remains to be determined The aim of this study was to analyze the efficacy and tolerance of concentrated concomitant split course radiochemotherapy. prognostic factors as well as those positively influencing complete response were also studied. Methods - This multicentric phase II trial looked at patients with histologically proven, inoperable, squamous cell esophageal carcinoma without metastases or invasion of the tracheobronchial mucosa. Treatment included 3 cycles of chemotherapy by 5-FU continuous infusion (800 mg/m(2).d D1-D5, D22-D26, D43-D47) cisplatin (70 mg/m(2) D2, D23, D44) and radiotherapy 15 Gy/5d (D1-D5, D22-26, D43-D47). Efficacy was analyzed by endoscopy, biopsy and computerized axial tomography during the 12(th) week of treatment. Results - The trial included 122 patients from 21 centers (110 M and 12 F, mean age 63.1 +/- 8.6 years, range 40 - 78). In accordance with the TNM-UICC classification (1978), 8 patients were classified stage I (T1 N0) 13 stage II (T2 N0), 100 stage III (T3 and/or N1) and stage was unknown in 1 patient. Median follow-vp was 63 months. Treatment was complete in half of the patients. 5 premature deaths (4.1%) were recorded over the treatment period, of which was directly linked to the toxicity of the the treatment. 16% of patients showed at least one severe side-effect. 117 patients received all 3 cycles of the treatment 88 of them without delay, and all were evaluated. 58 (47.5% of the patients included) showed a complete response with a negative biopsy, 36 (29.5%) showed a partial response, 13 (10.7%) were stable and 10 (8.2%) showed progressive disease. The median duration of complete responses wets 11.5 months. Symptomatically, dysphagia improved in 80% of the the cases, performance status in 40%, and weight gain was observed in 30% of the patients with weight loss. At evaluation, oral feeding was impossible in 4 patients only and possible in 113 patients; however, endoscopic treatment of the dysphagia remained necessary in 28 patients. Median survival in the 122 patients included was 13.0 +/- 1.6 months and survival rates were 52.9, 29.8 and 12.1% at 1, 2 and 5 years, respectively. Three pretherapeutic prognostic factors influenced survival in a multivariate analysis: initial severe dysphagia (risk of premature death increased 3-fold in the first year), circumferential extension and the differentiated nature of the tumor (risk of death doubled regardless of the time delay). Factors influencing a complete clinical response were on early tumor siege, a poorly differenciated tumor in patients older than 65, and no circumferential extension. The risk of recurrence was 54.8% at 1 year in the 58 Patients with complete remission. Complete circumferential extension and a well or moderately differentiated tumour influenced recurrence. Conclusion - This trial confirms the efficacy and good tolerance of concentrated split course radiochemotherapy in patients with inoperable esophageal cancer with a 5-year survival rate of 12%. This reinforces the need fbr a comparative trial (split course irradiation vs standard irradiation) such as the one currently being conducted in France.

Published
2000

5. Phase II trial of Vinorelbine in metastatic squamous cell esophageal carcinoma

Author

Conroy, T., Etienne, P.L., Adenis, A., Wagener, D.J.T., Paillot, B., Francois, E., Bedenne, L., Jacob, J.H., Seitz, J.F., Bleiberg, H., Pottelsberghe, C. van, Glabbeke, M. van, Delgado, F.M., Merle, S., and Wils, J.

Subjects
Experimental diagnostics and therapy of malignancies, Blood Cells, Leukemia, Lymphoma, Mycoses, Bacterial Infections, Infection, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Combined Modality Therapy, Magnetic Resonance Imaging
Abstract

Contains fulltext : 22716___.PDF (Publisher’s version ) (Open Access)

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results